AIDA.US Aida Pharmaceuticals Inc
- Market cap
- -
- P/E
- -
- P/B
- 0.77x
- ROE
- -65.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2008.
Is AIDA.US undervalued?
Graham numberThe Graham number of Aida Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aida Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Aida Pharmaceuticals Inc yet.
Aida Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aida Pharmaceuticals Inc
Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form,…
Full company profileAida Pharmaceuticals Inc financial statements
2008 annualized: Fiscal year 2008 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2008, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aida Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2004 | 2005 | 2006 | 2007 | 2008 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 15.6M | 24.5M | 29.6M | 29.2M | 40.6M |
| Gross Profit | 11.0M | 16.2M | 15.6M | 14.7M | 22.7M |
| Operating Income | 2.86M | 2.12M | 3.94M | 5.45M | 12.9M |
| EBITDA | 3.63M | 3.81M | 6.02M | 7.32M | -1.67M |
| Net Income | 1.64M | 1.47M | 1.45M | 2.74M | -6.00M |
| EPS | 0.07 | 0.06 | 0.06 | 0.10 | -0.22 |
| Balance Sheet | |||||
| Total Assets | 25.2M | 42.7M | 53.8M | 62.7M | 74.0M |
| Total Liabilities | 18.6M | 32.4M | 38.3M | 41.5M | 56.6M |
| Shareholders' Equity | 6.67M | 6.72M | 10.4M | 13.3M | 9.16M |
| Cash & Short-term Investments | 0.00 | 3.13M | 6.48M | 19.0M | 9.98M |
| Total Debt | - | 25.2M | 29.6M | 33.4M | 41.2M |
| Cash Flow | |||||
| Operating Cash Flow | -2.52M | 6.12M | 2.66M | 8.39M | 5.71M |
| Capital Expenditure | 1.16M | 700K | 2.97M | 3.61M | 5.03M |
| Free Cash Flow | - | 5.42M | -308K | 4.78M | 677K |
| Ratios | |||||
| ROE | 24.5% | 21.8% | 14.0% | 20.6% | -65.5% |
| ROA | 6.5% | 3.4% | 2.7% | 4.4% | -8.1% |
| Net Profit Margin | 10.5% | 6.0% | 4.9% | 9.4% | -14.8% |
| Debt to Equity | - | 3.74x | 2.85x | 2.51x | 4.49x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aida Pharmaceuticals Inc dividends
Aida Pharmaceuticals Inc has not paid dividends in the last 4 fiscal years.
Last stock split: 5:4 on Nov 30, 2005.
Who owns Aida Pharmaceuticals Inc
Ownership data of Aida Pharmaceuticals Inc is not available yet.
Aida Pharmaceuticals Inc company profile
- Company name
- Aida Pharmaceuticals Inc
- Ticker
- AIDA.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 450
- Fiscal year end
- December
- Address
- 31 Dingjiang Road, Hangzhou, China, 310016
- Phone
- 86 571 8580 2712
- Website
- -
About Aida Pharmaceuticals Inc
Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, manufacture, sales, and marketing of pharmaceutical and genetic products in mainland China. It offers antibiotics, cardiovascular, and anti-cancer drugs. The company provides its products in the form of powder for injection; and liquid for intravenous injection, capsule, tablet, and ointment. The company provides Etimicin Sulfate, an injectable powder form, as well as rh-Apo2l, a biopharmaceutical therapy for cancers. Aida Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Hangzhou, China.
Aida Pharmaceuticals Inc management
4- Mr. Biao JinChairman and Chief Executive Officer · born 1948
- Ms. Lin HuiChief Financial Officer and Principal Accounting Officer · born 1966
- Mr. Yue Jun JiangChief of Investment Department and Secretary · born 1975
- Mr. Qiu JiajunMember of Compensation Committee and Director · born 1966